共 50 条
- [21] Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study Breast Cancer Research and Treatment, 2014, 146 : 153 - 162
- [24] Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial LANCET, 2016, 388 (10063): : 2997 - 3005
- [25] A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer CANCER MEDICINE, 2014, 3 (02): : 293 - 299
- [28] Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06): : 753 - 760
- [30] A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer Breast Cancer Research and Treatment, 2013, 139 : 441 - 451